(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Overview

About this study

The purpose of this study is to test neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Primary localized uveal melanoma requiring either enucleation or plaque brachytherapy

- Able to dose orally

- ECOG Performance status of 0-1

- No other significant underlying ocular disease

- Adequate organ function

- Not pregnant/nursing or planning to become pregnant. Willing to use birth control

Exclusion Criteria:

- Previous treatment with a Protein Kinase C (PKC) inhibitor

- Concurrent malignant disease

- Active HIV infection or Hep B/C

- Malabsorption disorder

- Unable to discontinue prohibited medication

- Impaired cardiac function or clinically significant cardiac disease

- Any other condition which may interfere with study interpretation or results

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 11/13/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lauren Dalvin, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available